Macquarie Group LTD Tg Therapeutics, Inc. Transaction History

Macquarie Group LTD

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$4.57 - $8.4 $30,079 - $55,288	-6,582 Reduced 64.59%	3,608 $60,000
Q2 2022 Aug 15, 2022	BUY	$3.74 - $10.66 $19,268 - $54,920	5,152 Added 102.26%	10,190 $43,000
Q4 2021 Feb 11, 2022	BUY	$15.2 - $35.51 $13,345 - $31,177	878 Added 21.11%	5,038 $96,000
Q3 2021 Nov 12, 2021	BUY	$21.78 - $40.45 $27,813 - $51,654	1,277 Added 44.29%	4,160 $138,000
Q1 2021 May 14, 2021	BUY	$41.61 - $54.3 $10,860 - $14,172	261 Added 9.95%	2,883 $139,000
Q2 2020 Aug 11, 2020	BUY	$8.9 - $21.84 $23,335 - $57,264	2,622 New	2,622 $51,000
Q1 2019 May 15, 2019	SELL	$4.02 - $8.04 $2,009 - $4,019	-500 Closed	0 $0
Q3 2018 Nov 15, 2018	SELL	$5.15 - $14.0 $345,570 - $939,414	-67,101 Reduced 99.26%	500 $3,000
Q2 2018 Aug 14, 2018	BUY	$12.5 - $15.0 $192,212 - $230,655	15,377 Added 29.44%	67,601 $889,000
Q1 2018 May 11, 2018	BUY	$8.7 - $16.8 $454,348 - $877,363	52,224 New	52,224 $742,000

415

88.1M

2.34M

1.94M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $5.1B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

Stay updated on Macquarie Group LTD with notifications on news.